Overview

• On August 6, President Trump said duties on imported pharmaceuticals would start low before rising to 150% within 12 months and reaching 250% over 18 months to drive reshoring of manufacturing
• A late-July US-EU trade agreement secures a 15% tariff ceiling on European drug exports, though that rate applies for only about a year to a year and a half
• An executive order excludes Indian generics from the initial tariff round, a move confirmed by the Indian Pharmaceutical Alliance as part of the Section 232 probe
• Irish Taoiseach Micheál Martin and industry groups warn that steep tariffs could damage US-based pharma operations abroad and push up costs for patients
• Health-economics studies indicate even a 25% pharma duty could add roughly $51 billion to annual US drug spending and experts caution higher rates may disrupt generics supply and curb R&D